Life Sciences

Why real-world evidence is a game changer for life sciences in the age of value-based care

by Jared Kimble Value-based care is quickly becoming integral to the life sciences industry as the entire healthcare sector undergoes increased convergence. What that demands for pharmaceutical companies is better insight into the fair market value their products bring, or potentially will bring, to maximize all the benefits of those products. From a commercial viewpoint, […]

The possibilities of AI: A journey into the future of healthcare

by David Pare Artificial intelligence (AI), machine learning and deep learning have become entrenched in the professional world. AI-style capabilities are being embraced and developed globally (over 26 countries/regions have or are working on a national AI strategy) for many different purposes — from ethics, policies and education to security, technology and industry, the scope […]

Salud conectada: ¿por qué es tan importante la movilidad para el médico?

Los expertos en tecnología a menudo hablan de los beneficios de la movilidad en la atención médica, pero para comprender por qué resulta tan importante y cómo se puede mejorar el servicio sanitario prestado a los pacientes, es vital conocer su punto de vista. Como médico, mi visión de la movilidad está influenciada por mis […]

Real-world evidence and its role in healthcare and life sciences

by Dr. Richard Swafford, Senior Principal Industry Strategist Data is integral to what the life sciences industry does. To establish and run clinical trials, companies depend on data about the disease state, the molecule they are working with, similar products on the market and, most crucially, the patient. Aside from advancing clinical trial recruitment, access […]

Why opening spend analytics data to all decision makers will reduce costs

by Martin Bolden Spend analytics information has traditionally been closely guarded by procurement. But this approach is arguably a lost opportunity for both procurement and the wider business. Spending decisions are regularly made by other functions, so for a business to derive the best value and outcome from those decisions, spend analytics information must be […]

China gets ready to launch eCTD, as companies face a challenging learning curve

by Winnie Yang and Leslie Wan China is gearing up for the implementation of electronic Common Technical Document (eCTD) submissions to accelerate the review and approval of new pharmaceuticals. A year after officially introducing the subject, the life sciences industry in this country is starting to see greater momentum toward implementation. Publication of official specifications […]

Connected healthcare: Why mobility matters to the clinician

Doctor Using Cell Phone in Hallway

by Dr. Shainal Nathoo Technology experts will often talk about the benefits of mobility in healthcare, but to understand why mobility matters and how it might improve both workflow and clinical benefits for patients, it’s vital to get a user’s perspective. As a clinician, my view of mobility is influenced by my own experiences in […]

Reimagining patient centricity and healthcare practitioner engagement for 2020

by Satish Pandelenghat and Manjunath Shanabag The relationship between the life sciences industry and healthcare practitioners has changed dramatically in recent years. It wasn’t that long ago that sales reps visited each practice to provide information about new products. That changed in the late 1990s and early 2000s as information became more digital. Now what […]

4 considerations when choosing a solution for managing global regulatory submissions

by Dawn Waite and Sadia Ahmed There are so many balls in the air when managing global regulatory submissions that it’s all too easy to lose sight of the bigger picture. That picture really should be focusing on the portfolio, building your regulatory intelligence and strengthening your position in the market. But the day-to-day strain […]

Transforming pharma’s customer value chain with digital technologies

by Satish Nair and Manjunath Shanabag Pharmaceutical companies struggle with a complex and, often, poorly managed partner, customer and distribution network. It’s not surprising, given the makeup of most large pharma companies. Large, often disconnected product portfolios are built through discovery — both internally and externally with academia and biotech partners — and global clinical […]